8-K filing — Spyre Therapeutics, Inc. (SYRE)
Filed: 2026-10-07 AccNo: 0001628280-26-065291 Size: 590 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
JP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings
U.S. stocks rose Tuesday: Dow +350 points, S&P 500 +0.86%. Lamb Weston jumped 12% on strong results; Arrivent plunged 58%.
Spyre Therapeutics shares are trading lower after the company announced the pricing of its $350 million offering of 4,117,648 shares at $85.00 per share.
Reported Earlier, Spyre Therapeutics Prices $350M Public Offering Of 4,117,648 Common Shares At $85.00 Per Share, Plans To Fund Gastroenterology, Rheumatology And Dermatology Programs